CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Incyte cuts early-stage cancer drug to focus on next-gen programs

JakafiNegative
AI Analysis

Summary

Incyte is discontinuing an early-stage cancer drug program to prioritize late-stage development as the company prepares for the 2028 patent expiration of its flagship product Jakafi.

Importance:4/10
Sentiment:
-0.30
portfolio_restructuringpatent_cliffearly_stage_program_discontinuation
Related Companies

Read the original article

Published by BioSpace on July 29, 2026 12:56 PM

Read Original